Abstract

The aim of the study was to analyze the relationship between monocyte subpopulations and phenotype/ functions of monocyte-derived dendritic cells (DCs), as well as DC sensitivity to the tolerogenic effect of dexamethasone.Materials and methods. The study included 15 healthy donors. DCs were generated by cultivating enriched fractions of CD14+ monocytes with or without CD16+cell depletion (CD16-Mo-DCs or CD16+Mo-DCs, respectively) in the presence of interferon alpha (IFNα) and granulocyte-macrophage colony-stimulating factor (GM-CSF). Monocyte subpopulations were obtained by immunomagnetic negative selection.Results. CD16+Mo-DCs were characterized by higher percentage of mature (CD83+CD14-) and lower number of semi-mature (CD14+CD83+) cells, but were similar to CD16-Mo-DCs by HLA-DR and CD86 expression, involved in the presentation of antigens and activation of naive T-cells. and also to co-inhibitory/ tolerogenic molecules B7-H1 and TLR-2. CD16+Mo-DCs displayed higher allostimulatory activity, which was positively correlated with CD86 expression (rS = 0.69; p = 0.027) and negatively – with TLR-2 expression (rS = -0.72; p = 0.1). Allostimulatory activity of CD16-Mo-DCs was positively correlated with the number of mature CD14-CD83+DCs and semi-mature CD14+CD83+DCs. Addition of dexamethasone (10-6 M) into CD16-Mo-DCs and CD16+Mo-DCs cultures led to the delay of DC maturation, the decrease of CD86 and the increase of TLR-2 expression, as well as the increase of cells with co-inhibitory CD86- B7-H1+ phenotype that was positively correlated with the reduction of DC allostimulatory activity. The decrease of CD86+/TLR-2+ index in CD16+Mo-DC population was due to the reduction of CD86+DCs and in CD16-Mo-DC population – to the increase of TLR-2+cells. Dexamethasone possessed higher inhibitory effect on DC maturation in the CD16+Mo-DC cultures.Conclusion. CD14+ monocytes, both contained and depleted by CD16+ cells, can differentiate into DCs when cultured with IFNα. The presence of CD16+ cells in whole blood monocyte pool is associated with generation of DCs showed a more mature phenotype and higher allostimulatory activity. Both CD16- and CD16+ monocyte-derived DCs are sensitive to suppressive effect of dexamethasone. However, dexamethasone tolerogenic effect involves different mechanisms in CD16-Mo-DCs and CD16+Mo-DCs.

Highlights

  • The study approved by the local ethics committee under Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology (Protocol No 104 оf 12.01.2018)

  • Ostanin Alexander A., DM, Professor, Main Researcher, Laboratory of Cellular Immunotherapy, RIFCI, Russian Federation

Read more

Summary

ОБЗОРЫ И ЛЕКЦИИ REVIEWS AND LECTURES

Фенотип и функции дендритных клеток человека, генерированных из субпопуляций моноцитов CD14+, оппозитных по экспрессии CD16. Анализ взаимосвязи между субпопуляционной принадлежностью моноцитов и фенотипом и (или) функциями генерируемых дендритных клеток (dendrite cells, DC), а также их чувствительностью к толерогенному действию дексаметазона. Аллостимуляторная активность CD16−Мо-DC находилась в прямой взаимосвязи с количеством зрелых CD14−CD83+DC и CD14+CD83+DC промежуточной степени зрелости. Добавление дексаметазона (10−6 M) в культуры CD16−Мо-DC и CD16+Мо-DC сопровождалось задержкой созревания DC, снижением экспрессии CD86 и повышением TLR-2, а также увеличением количества клеток с ингибиторным фенотипом CD86−B7-H1+, что, в свою очередь, ассоциировалось со снижением аллостимуляторной активности DC. DC, генерированные из субпопуляций моноцитов, оппозитных по экспрессии CD16, характеризуются чувствительностью к супрессорному эффекту дексаметазона. При этом толерогенная активность дексаметазона в субпопуляциях CD16−Мо-DC и CD16+Мо-DC опосредуется с вовлечением различных механизмов. Авторы декларируют отсутствие конфликтов интересов, связанных с публикацией настоящей статьи

Оригинальные статьи
Фенотип и функции дендритных клеток человека
МАТЕРИАЛЫ И МЕТОДЫ
Контроль Control
Статистическую обработку данных проводили при помощи пакета прикладных программ
Вклад авторов
Authors contribution
Сведения об авторах
Findings
Authors information

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.